BMO Capital Reiterates Outperform Rating on Verve Therapeutics (VERV), PT $30
Tweet Send to a Friend
BMO Capital analyst Kostas Biliouris reiterated an Outperform rating and $30.00 price target on Verve Therapeutics (NASDAQ: VERV).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
